eyeonics
Founded Year
1998Stage
Acquired | AcquiredTotal Raised
$43.5MAbout eyeonics
Unlike standard cataract replacement lenses, Crystalens lenses correct their cataracts and give users back their range of vision. They flex like their eye's natural lens, allowing users to see better at all distances.
Missing: eyeonics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: eyeonics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest eyeonics News
Dec 8, 2022
News provided by Share this article SC9 Incorporates 21 Patented Features Designed to Position the Lens for Superior Intermediate Vision ALISO VIEJO, Calif., Dec. 8, 2022 /PRNewswire/ -- CORD, LLC, a privately held ophthalmic medical device company, announced today that it has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Model SC9 Intraocular Lens (IOL) for the treatment of cataracts. Model SC9 Intraocular Lens The SC9 is the brainchild of Stuart Cumming, MD, FACS, FRCOphth, who has been at the forefront of technology to improve and enhance vision for more than four decades. He is a pioneer in IOL research and development, with over one hundred patents related to intraocular lenses. Dr. Cumming designed the Crystalens®, approved by the FDA in 2003. The SC9 lens was designed to treat cataract patients with a single focus spherical optic and a rigid structure to consistently locate the optic in a position intended to provide intermediate vision that is superior to that of a standard monofocal IOL. CORD is seeking market approval of the SC9 intraocular lens based on the results of more than 300 patients who were followed for a minimum of one year under an approved Investigational Device Exemption (IDE). ABOUT CORD, LLC AND INVENTOR STUART CUMMING, MD Cumming Ophthalmic Research and Development (CORD, LLC) is a privately held ophthalmic medical device company founded by Dr. Stuart Cumming, MD. The Model SC9 represents Dr. Cumming's latest breakthrough in vision technology. After patenting and sequentially developing the six iterations of the Crystalens design and conducting clinical trials in Germany, Dr. Cumming co-founded Eyeonics in 1998. The Crystalens was approved by the FDA in November 2003 as the first and only accommodating IOL. Eyeonics was purchased by Bausch + Lomb in 2008. The Model SC9 lens is the result of 28 years of research, coupled with Dr. Cumming's expertise and continued devotion to IOL research and development. Media Contact
eyeonics Frequently Asked Questions (FAQ)
When was eyeonics founded?
eyeonics was founded in 1998.
Where is eyeonics's headquarters?
eyeonics's headquarters is located at 26970 Aliso Viejo Parkway, Aliso Viejo.
What is eyeonics's latest funding round?
eyeonics's latest funding round is Acquired.
How much did eyeonics raise?
eyeonics raised a total of $43.5M.
Who are the investors of eyeonics?
Investors of eyeonics include Bausch & Lomb UK, Brentwood Associates, Pequot Venture Capital, Versant Ventures, ABS Ventures and 3 more.
Who are eyeonics's competitors?
Competitors of eyeonics include Powervision, Paragon Medical, Visioneering Technologies, Samsara Vision, Ocular Therapeutix and 13 more.
Compare eyeonics to Competitors
Otothera Corporation is a medical device company developing products to diagnose and treat the more than seven million severe tinnitus (constant ringing in the ears) sufferers in the US. The company was originally named AudioFusion. The company was a 2006 PTEN Growth Accelerator (GAP) winner.
ImpediMed is a medical device company focusing on bioimpedance.
TheraTogs, based in Telluride, Colorado, is a medical device company offering orthotic undergarment and strapping systems that give users with sensorimotor impairment modality for improving postural alignment and stability movement skill and precision and joint stability.
Exergen Corporation is the recognized world leader in industrial and medical non-invasive temperature technology. From providing temperature sensors for NASA and various industries to creating one of the world's most popular baby gifts, Exergen creates non-invasive temperature measurement devices providing lower cost, higher accuracy, less invasiveness, and greater reliability than ever previously possible. The creator of a temporal artery thermometer-the Temporal Scanner, the most efficacious, non-invasive thermometer ever created. Exergen holds over 100 U.S. and foreign patents, and is the only manufacturer of retail medical thermometers in the U.S. Presently, 30% of hospitals and pediatricians currently use the Exergen TemporalScanner, and well over 1 million consumers use one at home. Founded by Harvard-research scientist .Dr. Francesco Pompei over two decades ago, Exergen Corporation is based in Watertown, Massachusetts, USA.
The company are a enterprise recognized in the enteral products industry as a manufacturer of high quality, yet cost-effective devices. The company supply products to domestic and international customers. The company also are a contract manufacturer focused on the development and production of equipment for the medical and life sciences industries. The company's organization is composed of individuals with years of industry experience. OST Medical has a strong commitment to the company's customers and the company are confident in the company's ability to meet customer expectations in quality, price and delivery.
Intelligent Orthopaedics, the designers of STORM (The staffordshire orthopaedic reduction machine) for the reduction of tibial fractures and IOS the flexible, single use fixator
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.